---
title: "INTERPACE BIOSCIENCES, INC. (IDXG) news: reverse split"
url: "https://aibio.space/companies/interpace-biosciences/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "IDXG reverse split news: Interpace Biosciences sets 1-for-5 reverse stock split to support Nasdaq bid. INTERPACE BIOSCIENCES, INC."
---

IDXG INTERPACE BIOSCIENCES, INC. OTC · United States

# INTERPACE BIOSCIENCES, INC. (IDXG) news IDXG reverse split news

Company Updates · 2026-10-14

## [Interpace Biosciences expects third quarter revenue of $10.1 million to $10.4 million](https://aibio.space/news/interpace-biosciences-expects-third-quarter-revenue-10-1-million-10-4/)

The preliminary, unaudited range is approximately 11% to 14% above the second quarter of 2026 and approximately 15% to 18% above the third quarter of 2025.

## Latest INTERPACE BIOSCIENCES, INC. news

1. 2026-08-26 Listings [Interpace Biosciences sets 1-for-5 reverse stock split to support Nasdaq bid](https://aibio.space/news/interpace-biosciences-sets-1-5-reverse-stock-split-support-nasdaq-bid/) The split takes effect August 27, 2026 and reduces outstanding shares from approximately 27.7 million to approximately 5.5 million, aimed at Nasdaq's minimum bid price requirement.
2. 2026-08-10 Company Updates [Interpace Biosciences reports second quarter revenue of $9.1 million](https://aibio.space/news/interpace-biosciences-reports-second-quarter-revenue-9-1-million/) Revenue was $9.1 million, down slightly from the prior-year quarter as reported, while income from continuing operations was $0.3 million and thyroid revenue rose 9%.
3. 2026-05-12 Company Updates [Interpace Biosciences reports first quarter revenue of $9.0 million](https://aibio.space/news/interpace-biosciences-reports-first-quarter-revenue-9-0-million/) Revenue was $9.0 million, down 22% from the prior-year quarter as reported and up 14% on a pro forma basis, and the company reaffirmed its 2026 thyroid growth guidance.

## INTERPACE BIOSCIENCES, INC. at a glance

- **Ticker**: IDXG

- **Listing**: OTC

- **Country**: United States

- **Cash, Jun 30, 2026**: $2.7 million

### Related companies

- [iTonic Holdings](https://aibio.space/companies/itonic/) NASDAQ: ITOC
- [INTUITIVE SURGICAL INC](https://aibio.space/companies/intuitive-surgical/) NASDAQ: ISRG
- [IceCure Medical](https://aibio.space/companies/icecure-medical/) NASDAQ: ICCM
- [IQVIA HOLDINGS INC.](https://aibio.space/companies/iqvia/) NYSE: IQV
- [ALCON INC](https://aibio.space/companies/alcon/) NYSE: ALC
- [CYANOTECH CORP](https://aibio.space/companies/cyanotech/) OTC: CYAN
- [908 Devices](https://aibio.space/companies/908-devices/) NASDAQ: MASS
- [Edwards Lifesciences](https://aibio.space/companies/edwards-lifesciences/) NYSE: EW

### Also on OTC

- [Burzynski Research Institute](https://aibio.space/companies/burzynski-research-institute/) BZYR
- [SCIENTIFIC INDUSTRIES INC](https://aibio.space/companies/scientific-industries/) SCND
- [Emmaus Life Sciences](https://aibio.space/companies/emmaus-life-sciences/) EMMA
- [Devonian Health Group](https://aibio.space/companies/devonian-health-dvhgf/) DVHGF
- [Nymox Pharmaceutical](https://aibio.space/companies/nymox-pharmaceutical/) NYMXF
- [VASO](https://aibio.space/companies/vaso/) VASO

## INTERPACE BIOSCIENCES, INC. annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | [$642,000](https://www.sec.gov/Archives/edgar/data/1054102/000149315226013646/) | [$676,000](https://www.sec.gov/Archives/edgar/data/1054102/000149315226013646/) |
| Net income (loss) | [$24.6 million](https://www.sec.gov/Archives/edgar/data/1054102/000149315226013646/) | [$6.7 million](https://www.sec.gov/Archives/edgar/data/1054102/000149315226013646/) |
| Cash from operations | [$5.8 million](https://www.sec.gov/Archives/edgar/data/1054102/000149315226013646/) | [$4.6 million](https://www.sec.gov/Archives/edgar/data/1054102/000149315226013646/) |
| Cash and equivalents | [$2.5 million](https://www.sec.gov/Archives/edgar/data/1054102/000149315226036895/) | [$1.5 million](https://www.sec.gov/Archives/edgar/data/1054102/000149315226013646/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $2.7 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about INTERPACE BIOSCIENCES, INC.

Did INTERPACE BIOSCIENCES, INC. do a reverse stock split?

Our latest story on this, dated Aug 26, 2026: "Interpace Biosciences sets 1-for-5 reverse stock split to support Nasdaq bid". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/interpace-biosciences-sets-1-5-reverse-stock-split-support-nasdaq-bid/).

What is the ticker symbol of INTERPACE BIOSCIENCES, INC.?

INTERPACE BIOSCIENCES, INC. trades under the ticker IDXG on OTC.

Where is INTERPACE BIOSCIENCES, INC. listed?

INTERPACE BIOSCIENCES, INC. is listed on OTC.

Which country or territory is INTERPACE BIOSCIENCES, INC. listed under?

Our directory records INTERPACE BIOSCIENCES, INC. under United States.

Does aibio.space cover INTERPACE BIOSCIENCES, INC.?

aibio.space lists INTERPACE BIOSCIENCES, INC. among 2,820 public biotech companies and publishes its news here as stories appear.

Is INTERPACE BIOSCIENCES, INC. profitable?

INTERPACE BIOSCIENCES, INC. reported net income of $24.6 million for the fiscal year ended Dec 31, 2025, and generated $5.8 million of cash from operations, per its annual report to the SEC.

How much does INTERPACE BIOSCIENCES, INC. spend on research and development?

$642,000 in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does INTERPACE BIOSCIENCES, INC. have?

$2.7 million in cash at Jun 30, 2026, per its 10-Q.

What is the latest INTERPACE BIOSCIENCES, INC. (IDXG) stock news?

Our latest story on INTERPACE BIOSCIENCES, INC., dated Oct 14, 2026: "Interpace Biosciences expects third quarter revenue of $10.1 million to $10.4 million". The preliminary, unaudited range is approximately 11% to 14% above the second quarter of 2026 and approximately 15% to 18% above the third quarter of 2025. [Source](https://aibio.space/news/interpace-biosciences-expects-third-quarter-revenue-10-1-million-10-4/).

How can I follow INTERPACE BIOSCIENCES, INC. (IDXG) news?

Press Follow on this page to add INTERPACE BIOSCIENCES, INC. to your Following list, or subscribe to the aibio.space newsletter. We have published 4 stories naming INTERPACE BIOSCIENCES, INC. so far, in Company Updates, Listings.

## Investor discussion: INTERPACE BIOSCIENCES, INC.

Members talk about INTERPACE BIOSCIENCES, INC. (IDXG). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at INTERPACE BIOSCIENCES, INC., newest first. Each line links the filing it comes from.

1. 2026-09-25 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1054102/000149315226044208/forms-1.htm)
2. 2026-08-27 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1054102/000149315226040329/ex99-1.htm)
3. 2026-08-21 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1054102/000149315226039530/form8-k.htm)
4. 2026-07-07 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1054102/000149315226032369/formdef14a.htm)
5. 2026-06-25 Mergers Filed documents for a merger or acquisition. SEC Form PREM14A. [Source](https://www.sec.gov/Archives/edgar/data/1054102/000149315226029987/formprem14a.htm)
6. 2026-06-23 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1054102/000149315226029801/formpre14a.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:IDXG on TradingView](https://www.tradingview.com/symbols/OTC-IDXG/).

## Listing details

INTERPACE BIOSCIENCES, INC. is a public biotech or pharmaceutical company listed on OTC under the ticker IDXG, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: INTERPACE BIOSCIENCES, INC.

- **Ticker**: IDXG

- **Listing**: OTC

- **Country or territory**: United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/interpace-biosciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "INTERPACE BIOSCIENCES, INC. (IDXG) news: reverse split", 2026-10-31, https://aibio.space/companies/interpace-biosciences/